Home » Stocks » VYGR

Voyager Therapeutics, Inc. (VYGR)

Stock Price: $4.73 USD -0.11 (-2.27%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $4.90 +0.17 (3.59%) Jun 11, 7:29 PM
Market Cap 178.45M
Revenue (ttm) 159.56M
Net Income (ttm) 39.36M
Shares Out 37.50M
EPS (ttm) 1.05
PE Ratio 4.52
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $4.73
Previous Close $4.84
Change ($) -0.11
Change (%) -2.27%
Day's Open 4.86
Day's Range 4.68 - 4.93
Day's Volume 347,392
52-Week Range 3.89 - 14.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Voyager Therapeutics, Inc (NASDAQ: VYGR) CEO and President Andre Turenne will step down as the beleaguered company announced it would move focus to early, discovery-stage efforts. The company's CMO and ...

3 weeks ago - Benzinga

Company focusing on rapidly moving VY-HTT01 into clinical development for Huntington's disease and maximizing opportunities created by TRACER TM gene therapy technology platform and next-generation targ...

3 weeks ago - GlobeNewsWire

Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody. The results will be presented at the Amer...

1 month ago - Benzinga

Findings to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurologica...

1 month ago - GlobeNewsWire

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 18.31% and 35.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

- On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington's disease in the fourth quarter of 2021

1 month ago - GlobeNewsWire

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more ...

1 month ago - Zacks Investment Research

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...

Other stocks mentioned: AXSM, QURE, CRSP, RVPH
1 month ago - Benzinga

Today FDA has removed the clinical hold on one more gene therapy study, this time for Voyager Therapeutics Inc's (NASDAQ: VYGR) investigational new drug application for VY-HTT01, a gene therapy candidat...

1 month ago - Benzinga

Los Angeles, California--(Newsfile Corp. - March 24, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeuti...

2 months ago - Newsfile Corp

NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and certain of ...

2 months ago - PRNewsWire

NEW YORK, March 23, 2021 /PRNewswire/ --  WHY:  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 ...

2 months ago - PRNewsWire

Sometimes a selloff is a sign of more pain to come, but these are 7 stocks to buy if you think a rebound may be close at hand. The post 7 Stocks for Value Investors to Buy Near Their 52-Week Lows appear...

Other stocks mentioned: CPNG, JOAN, MPLN, PLTK, RBLX, TLT
2 months ago - InvestorPlace

Los Angeles, California--(Newsfile Corp. - March 23, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeuti...

2 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - March 22, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeuti...

2 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - March 19, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeuti...

2 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - March 18, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between ...

2 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)-- #Inc--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and Novem...

2 months ago - Business Wire

Investors with losses are encouraged to contact the firm before March 24, 2021; click here to submit trade information

2 months ago - GlobeNewsWire

NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 20...

3 months ago - GlobeNewsWire

Los Angeles, March 12, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc. ("Voyag...

3 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 9, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between J...

3 months ago - Newsfile Corp

NEW YORK, March 8, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and...

3 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) a...

3 months ago - Newsfile Corp

LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021 LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021

3 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - March 3, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between J...

3 months ago - Newsfile Corp

NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and certain of i...

3 months ago - PRNewsWire

NEW YORK, Feb. 27, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017...

3 months ago - GlobeNewsWire

With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.

Other stocks mentioned: ABNB, EDIT, CNP, AGIO, DNLI, PTR, TREE ...
3 months ago - 24/7 Wall Street

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and...

3 months ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering...

3 months ago - GlobeNewsWire

LOS ANGELES, Feb. 25, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc. ("Voyager...

3 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR)...

3 months ago - Business Wire

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017...

3 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYG...

3 months ago - Newsfile Corp

LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021 LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021

3 months ago - GlobeNewsWire

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2...

3 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - February 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) betwe...

3 months ago - Newsfile Corp

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) from June 1, 2017...

3 months ago - GlobeNewsWire

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and certain of i...

3 months ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurologica...

3 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - February 17, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) betwe...

3 months ago - Newsfile Corp

NEW YORK, Feb. 16, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or...

3 months ago - PRNewsWire

NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of   Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...

3 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYG...

3 months ago - Newsfile Corp

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VYGR #ClassAction--Shareholder rights law firm Robbins LLP reminds shareholders that a purchaser of Voyager Therapeutics, Inc. (Nasdaq: VYGR) filed a c...

3 months ago - Business Wire

New York, New York--(Newsfile Corp. - February 10, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYG...

4 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - February 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therape...

4 months ago - Newsfile Corp

About VYGR

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's dise... [Read more...]

Industry
Biotechnology
IPO Date
Nov 11, 2015
CEO
G. Andre Turenne
Employees
177
Stock Exchange
NASDAQ
Ticker Symbol
VYGR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for VYGR stock is "Buy." The 12-month stock price forecast is 9.61, which is an increase of 103.17% from the latest price.

Price Target
$9.61
(103.17% upside)
Analyst Consensus: Buy